8-K: Virios Therapeutics Faces Nasdaq Delisting Notice, Requests Hearing to Present Compliance Plan

Virios Therapeutics has received a second delisting notice from Nasdaq for failing to maintain a minimum share price of $1.00 and has requested a hearing to present a plan for regaining compliance.

Summary

• Virios Therapeutics received a letter from Nasdaq on May 1, 2024, stating that its common stock had failed to maintain a minimum bid price of $1.00 per share for continued listing.
• This follows an initial notice received on November 7, 2023, which provided a 180-day period to regain compliance, ending April 30, 2024.
• The company has requested a hearing with Nasdaq to present a plan to regain compliance.
• The plan includes the anticipated receipt of data from the study of IMC-2 for Long-COVID treatment and a commitment to a reverse stock split if necessary.
• The request for a hearing has temporarily stayed the delisting of the company's common stock pending the Nasdaq hearing panel's decision.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. The potential reverse stock split is also a negative signal.

Positives

• The company has requested a hearing with Nasdaq, which has temporarily stayed the delisting.
• Virios has a plan to regain compliance, including the release of study data and a potential reverse stock split.

Negatives

• The company's stock price has fallen below the minimum $1.00 requirement for continued listing on Nasdaq.
• Virios has received a second delisting notice from Nasdaq.

Risks

• There is a risk that the Nasdaq hearing panel may not approve the company's plan to regain compliance.
• The company's stock could be delisted if the hearing is unsuccessful.
• The reverse stock split could negatively impact the stock price.

Future Outlook

The company intends to present a plan to regain compliance to the Nasdaq hearing panel, including the anticipated receipt of data from the study of IMC-2 for the treatment of Long-COVID and a commitment to effect a reverse stock split, if necessary.

Management Comments

• The company intends to present a plan to regain compliance to the Panel that includes a discussion of the events that we believe will enable us to regain compliance, including the anticipated receipt of data from the study of IMC-2 for the treatment of Long-COVID being conducted by the Bateman Horne Center as well as a commitment to effect a reverse stock split, if necessary.

Industry Context

This announcement highlights the challenges faced by smaller biotech companies in maintaining stock prices and meeting listing requirements, particularly during periods of market volatility or when clinical trial results are pending.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance, especially those with volatile stock prices due to clinical trial outcomes and funding needs.
• A reverse stock split is a common strategy used by companies to regain compliance with minimum bid price requirements, but it can be viewed negatively by investors.
• The success of Virios's plan hinges on the positive outcome of the IMC-2 study and the Nasdaq hearing panel's decision, similar to other biotech companies relying on clinical data for stock valuation.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may experience uncertainty regarding the company's future.
• The company's ability to raise capital may be impacted by the delisting notice.

Next Steps

• Virios will present its plan to regain compliance to the Nasdaq hearing panel.
• The company will await the Nasdaq hearing panel's decision regarding the delisting.

Key Dates

Keywords

delisting, Nasdaq, compliance, minimum bid price, reverse stock split, hearing, IMC-2, Long-COVID